NDA 022036 · Currax
Silenor
Doxepin Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Oct 29, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Mar 17, 2010
Approved uses
1
Original approval plus efficacy supplements
Registered trials
19
4 Phase 3, 3 recruiting
FAERS reports
2,564
1,560 serious, 369 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 21, 2026.
1. INDICATIONS AND USAGE SILENOR is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. The clinical trials performed in support of efficacy were up to 3 months in duration . SILENOR (doxepin) tablets are indicated for the treatment of insomnia characterized by difficulties with sleep maintenance. ( 1 , 14 )
Mechanism: The mechanism of action of doxepin in sleep maintenance is unclear; however, doxepin's effect could be mediated through antagonism of the H 1 receptor .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 17, 2010 Original approval · Type 3 - New Dosage Form Summary ReviewReviewLetter
2 products under this application
- SILENOR · DOXEPIN HYDROCHLORIDE EQ 3MG BASE · TABLET, ORAL · Prescription · TE AB
- SILENOR · DOXEPIN HYDROCHLORIDE EQ 6MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Doxepin" as an intervention, any sponsor and status, largest first.
- A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for InsomniaPivotal-lookingRecruiting
University of PennsylvaniaAcademic, hospital or other
NCT07542756 · 1,200 participants (planned) · Start May 1, 2026 · Primary completion Jan 1, 2032
Drug: Diphenhydramine, 25 mg; Diphenhydramine, 50 mg and 7 more · For: Insomnia; Insomnia Disorder; Chronic Insomnia and 1 more
Sites: Philadelphia, Pennsylvania
- Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic InsomniaPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00755495 · 472 participants · Start Jul 2006 · Primary completion Mar 2007
Drug: Ramelteon and doxepin; Ramelteon and 2 more · For: Sleep Initiation and Maintenance Disorders
- Pharmacovigilance in Gerontopsychiatric PatientsPivotal-lookingTerminated
Hannover Medical SchoolAcademic, hospital or other
NCT02374567 · 407 participants · Start Jan 2015 · Primary completion Jun 28, 2017
Drug: Phenobarbital; Phenytoin and 95 more · For: Dementia; Depression; Schizophrenia and 2 more
Sites: Augsburg, Germany; Berlin, Germany; Hanover, Germany · 5 sites in all
- Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without ChemotherapyPivotal-lookingCompleted
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT02229539 · 275 participants · Start Nov 18, 2014 · Primary completion May 23, 2016
Drug: doxepin hydrochloride oral solution; DLA (diphenhydramine, lidocaine and antacids) rinse · For: Acute Oral Mucositis Pain
Sites: Anchorage, Alaska; Burbank, California; Dublin, California · 350 sites in all
- Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal CarcinomaPivotal-lookingRecruiting
Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
NCT06017895 · 178 participants (planned) · Start Oct 31, 2023 · Primary completion Jul 31, 2026
Drug: doxepin solution · For: Swallowing-induced Pain
Sites: Guangzhou, China
- Using Doxepin for UrticariaPivotal-lookingStatus unknown
State University of New York - Upstate Medical UniversityAcademic, hospital or other
NCT05115136 · 160 participants (planned) · Start May 23, 2022 · Primary completion Jan 31, 2023
Drug: Doxepin; Diphenhydramine · For: Urticaria
Sites: Syracuse, New York
- Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without ChemotherapyPivotal-lookingCompleted
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT01156142 · 155 participants · Start Dec 2010 · Primary completion May 2012
Drug: doxepin hydrochloride · For: Head and Neck Cancer; Mucositis; Oral Complications of Radiation Therapy and 1 more
Sites: Scottsdale, Arizona; Hartford, Connecticut; Jacksonville, Florida · 120 sites in all
- Doxepin Alone or Combined With Ramelteon Versus Placebo for Improving Sleep Quality After Primary Total Knee ArthroplastyPivotal-lookingNot yet recruiting
University of WashingtonAcademic, hospital or other
NCT07598734 · 129 participants (planned) · Start Jun 2026 · Primary completion Jun 2028
Drug: Doxepin 6 mg; Ramelteon 8 mg and 1 more · For: Sleep Quality Post-TKA; Postoperative Knee Function; Quality of Life After Primary TKA
Sites: Seattle, Washington
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective278
- pain228
- insomnia203
- fatigue192
- completed suicide189
- dizziness186
- fall183
- toxicity to various agents168
- anxiety167
- headache153
- off label use145
- pruritus135
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 20 |
| 2005 | 36 |
| 2006 | 43 |
| 2007 | 15 |
| 2008 | 13 |
| 2009 | 24 |
| 2010 | 26 |
| 2011 | 25 |
| 2012 | 46 |
| 2013 | 52 |
| 2014 | 19 |
| 2015 | 55 |
| 2016 | 146 |
| 2017 | 152 |
| 2018 | 126 |
| 2019 | 223 |
| 2020 | 191 |
| 2021 | 194 |
| 2022 | 156 |
| 2023 | 169 |
| 2024 | 261 |
| 2025 | 335 |
| 2026 | 237 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Silenor (Doxepin HCl)
2024 spending
$504K
Beneficiaries
182
816 claims
Per beneficiary
$2,767
$16.78 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $13,046,161 |
| 2021 | $2,811,616 |
| 2022 | $1,379,343 |
| 2023 | $906,535 |
| 2024 | $503,609 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
De Crescenzo F, D'Alò GL, Ostinelli EG, et al. · Lancet 2022 · Network Meta-Analysis, Systematic Review
- The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis.
Pillinger T, Arumuham A, McCutcheon RA, et al. · Lancet 2025 · Network Meta-Analysis, Systematic Review
- Treatment of urticarial vasculitis: A systematic review.
Kolkhir P, Grakhova M, Bonnekoh H, et al. · J Allergy Clin Immunol 2019 · Research Support, Non-U.S. Gov't, Systematic Review
- Antidepressants for insomnia in adults.
Everitt H, Baldwin DS, Stuart B, et al. · Cochrane Database Syst Rev 2018 · Meta-Analysis, Systematic Review
- Pharmacological interventions for antipsychotic-related sialorrhea: a systematic review and network meta-analysis of randomized trials.
Fornaro M, Caiazza C, Solini N, et al. · Mol Psychiatry 2023 · Systematic Review, Network Meta-Analysis
- Adverse events of pharmacological interventions for insomnia disorder in adults: a systematic review and network meta-analysis.
Lu C, Geng Y, Guan X, et al. · Front Psychiatry 2025 · Systematic Review
Sponsor: Currax
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.